Inventor
Ming Fai Chan
Inventor
San Diego, CA, US
Overview
Patents· 40 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes33%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations21%
C07DHeterocyclic compounds21%
C07CAcyclic or carbocyclic compounds13%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests4%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium3%
C07HSugars3%
C07KPeptides1%
LOC141%
PatentTitleYear
7,605,144'Enzyme catalyzed therapeutic compounds'2009D0486148'Electronic organizer'20046,683,061'Enzyme catalyzed therapeutic activation'20046,613,804'Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin'20036,541,498'Benzenesulfonamides and the use thereof to modulate the activity of endothelin'20036,384,261'Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin'20026,376,523'Benzenesulfonamides and the use thereof to modulate the activity of endothelin'20026,342,610'N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin'20026,331,637'N-Alkyl, N-Alkenyl, N-Alkynyl, N-Aryl and N-fused bicyclo or tricyclo thienyl-, furyl-,and Pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin'20016,265,428'Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin'20016,258,844'Cyclopentane (ene) oic acid, 2-alkenyl derivatives as therapeutic agents'20016,030,991'Benzenesulfonamides and the use thereof to modulate the activity of endothelin'20005,977,117'Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin'19995,962,490'Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin'19995,958,905'Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin'19995,767,154'5-trans-prostaglandins of the F series and their use as ocular hypotensives'19985,736,509'Cyclic peptide surface feature mimics of endothelin'19985,656,635'5-trans-alcohols and their use as ocular hypotensives'19975,594,021'Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin'19975,591,761'Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin'19975,574,066'Intraocular pressure reducing 15-acyl prostaglandins'19965,571,821'Sulfonamides and derivatives thereof that modulate the activity of endothelin'19965,543,521'Compounds that modulate endothelin activity'19965,514,691'N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin'19965,476,872'1,11-diesters of prostaglandin-F.sub.2.alpha. having a polar ester group at C-1'19955,468,778'Method of lowering intraocular pressure by administering a pharmaceutical composition containing 7-(5-substituted cyclopentyl) and 7-(5-substituted-cyclopentenyl) 5-heptenoic acids and derivatives'19955,464,853'N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin'19955,446,041'Intraocular pressure reducing 11-acyl prostaglandins'19955,332,730'Azido derivatives of cyclopentane heptanoic or heptenoic acid'19945,328,933'Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues'19945,312,832'Ocular hypotensive 2-decarboxyl-2-acylthioalkyl prostaglandin derivatives'19945,312,842'Cyclopentane heptenylsulfinylalkyl and heptanylsulfinylalkyl-2-aliphatic or aryl aliphatic derivatives'19945,288,754'Polar C-1 esters of prostaglandins'19945,270,049'2-decarboxyl-2-aminoalkyl-prostaglandins as ocular hypotensives'19935,262,437'Homo-prostaglandin derivatives as ocular hypotensives'19935,238,961'PGF 1-alcohols and their use as ocular hypotensives'19935,139,491'2-decarboxyl-2-alkoxyalkyl prostaglandins as ocular hypotensives'19925,034,413'Intraocular pressure reducing 9,11-diacyl prostaglandins'19915,028,624'Intraocular pressure reducing 9,15-diacyl prostaglandins'19914,994,274'Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using'1991Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1991–1998Patents assigned to ALLERGAN INC (18)· patent assignee history
1991–1995Based in Santa Ana, CA, US· patent location history
1992–1993Based in Lake Bluff, IL, US· patent location history
1993–2003Based in San Diego, CA, US· patent location history
1995–1996Patents assigned to IMMUNOPHARMACEUTICS INC (3)· patent assignee history
1996–2002Patents assigned to TEXAS BIOTECHNOLOGY CORP (13)· patent assignee history
1998–2009Based in Encinitas, CA, US· patent location history
2001Patents assigned to ALLERGAN SALES INC (1)· patent assignee history
2004Patents assigned to BRILLIANT SYSTEM LTD (1)· patent assignee history
2004Based in Kowloon, CN· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ALLERGAN INC | 18 | 1991–1998 |
| TEXAS BIOTECHNOLOGY CORP | 13 | 1996–2002 |
| IMMUNOPHARMACEUTICS INC | 3 | 1995–1996 |
| ALLERGAN SALES INC | 1 | 2001 |
| BRILLIANT SYSTEM LTD | 1 | 2004 |
Locations
| Location | Patents | Span |
|---|---|---|
| San Diego, California, US | 26 | 1993–2003 |
| Encinitas, California, US | 5 | 1998–2009 |
| Santa Ana, California, US | 5 | 1991–1995 |
| Lake Bluff, Illinois, US | 2 | 1992–1993 |
| Kowloon, CN | 1 | 2004 |